ProCE Banner Activity


The Laboratory - Stewardship Partnership: Putting Susceptibility Testing Results for Gram Negative Organisms Into Practice


Watch this on-demand webcast of a live webinar for expert discussion of how pharmacists can review CLSI standards for antimicrobial susceptibility testing and reporting.


Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: August 17, 2022

Expiration: August 16, 2023

No longer available for credit.



Samuel L. Aitken

Samuel L. Aitken, PharmD, MPH, BCIDP

Adjunct Clinical Professor
University of Michigan College of Pharmacy
Clinical Pharmacist Specialist, Infectious Diseases
Department of Pharmacy
Michigan Medicine
Ann Arbor, Michigan

Tanis Dingle

Tanis Dingle, PhD, FCCM, D(ABMM)

Clinical Associate Professor
Department of Pathology and Laboratory Medicine
University of Calgary
Clinical Microbiologist
Public Health Laboratory
Alberta Precision Laboratories
Calgary, Alberta, Canada

Provided by

ProCE Banner
ProCE Banner

Additional Information

Program Medium

This program has been made available online.

Provided by ProCE, LLC and Clinical and Laboratory Standards Institute (CLSI) in collaboration with the Society of Infectious Diseases Pharmacists (SIDP) and ACCP ID PRN.

Target Audience

The target audience for this activity is pharmacists and laboratory professionals.

Learning Objectives

At the completion of this activity, the participant will be better able to:

  • Discuss the latest recommendations in the 2022 CLSI standards for antimicrobial susceptibility testing and reporting
  • Describe ways in which stewardship teams can utilize susceptibility testing results to optimize patient outcomes
  • Identify new opportunities for collaboration between stewardship and the microbiology laboratory


ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. 

ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Tanis Dingle, Ph.D., FCCM, D(ABMM): research support: AVIR Pharma

Samuel L. Aitken, PharmD, MPH, BCIDP: consultant/advisor/speaker: Entasis Therapeutics, Shionogi; research support: Melinta Therapeutics

The planners /managers reported the following relationships:

Melissa Johnson: consulting fees, grant support, royalties: Entasis, Merck & Co, Charles River Laboratories, Scynexis

Bruce Jones: consulting/speakers bureau: Paratek, Merck, Melinta, Abbvie, Abbvie, Paratek, LaJolla, Regeneron

ProCE staff and planners have no relevant financial relationships to disclose, except those listed above.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-199-H01-P has been assigned to this application-based enduring CE activity. This CE activity is approved for 1.5 contact hour (0.15 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.

Clinical and Laboratory Standards Institute is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program.